基于溶出特性评价附子理中丸的剂型特征

目的:基于前期对附子理中丸中甘草成分溶出度的研究结果,通过同时测定君药附子中的3种指标成分苯甲酰新乌头碱、苯甲酰乌头碱、苯甲酰次乌头碱的溶出度,进一步对附子理中丸的溶出行为进行研究,为该丸剂的质量控制提供依据,同时为该丸剂的体内释药行为研究奠定基础。方法:建立同时测定附子理中丸中苯甲酰新乌头碱、苯甲酰乌头碱、苯甲酰次乌头碱含量的HPLC-QQQ-MS;测定5个厂家共15批附子理中丸在不同时间点3种指标成分的溶出量,计算累积溶出度,绘制溶出曲线;采用f2相似因子法,比较同一厂家不同批次样品中3个指标成分溶出曲线的相似性和同一厂家样品中不同指标成分间溶出曲线的相似性;对溶出数据进行模型拟合以归属附子理中丸的溶出模型。结果:以p H 1. 2的盐酸溶液作为溶出介质时,3种生物碱溶出效果最为理想。附子理中丸中3种单酯型乌头碱的溶出基本同步,且溶出行为可持续到24 h。厂家1,3,4,5的各自3批样品之间溶出行为相似,表明绝大多数厂家样品溶出行为的相似度较好。厂家2中批次1样品与批次2,3样品的溶出行为存在一定的差异性,提示厂家2不同批次样品的质量可能存在一定差异性。不同厂家样品中有效成分的溶出数据拟合结果一致,且均以Weibull模型为最佳。结论:5个厂家15批样品中指标成分均在24 h内持续溶出,表明样品具有"丸者缓也"的缓慢溶释特征。同一厂家样品的溶出曲线相似情况总体较好,表明大多数厂家的批次间制剂质量具有稳定性。不同厂家样品间的苯甲酰新乌头碱、苯甲酰乌头碱、苯甲酰次乌头碱溶出曲线相似度具有一定的差异性,可能由于不同厂家的药材或制剂生产工艺参数不一致造成的。

Evaluation of Dosage form Characteristics of Fuzi Lizhongwan Based on Dissolution Behavior

Objective:Based on the previous studies, to investigate the dissolution behavior of Fuzi Lizhongwan by simultaneously determining the dissolution of benzoylmesaconine, benzoylaconine and benzoylhypaconine in Aconiti Lateralis Radix Praeparata. Method:The simultaneous determination of benzoylmesaconine, benzoylaconine and benzoylhypaconine in Fuzi Lizhongwan was established by HPLC-QQQ-MS. The dissolution amounts of three compositions in 15 batches of Fuzi Lizhongwan from 5 manufacturers at different time points, the cumulative dissolution was calculated and the dissolution curve was drawn. The f₂ similarity factor method was adopted to evaluate similarity of dissolution curves of index components in different batches of samples from the same manufacturer, and to evaluate similarity of dissolution curves of samples from different manufacturers based on the same index component. The dissolution model of Fuzi Lizhongwan was concluded by fitting with the dissolution data. Result:When hydrochloric acid solution with pH of 1.2 was used as the dissolution medium, the three alkaloids had the best dissolution effect. The dissolution behavior of three monoester alkaloids in Fuzi Lizhongwan was basically synchronous and the dissolution lasted for 24 h. Three batches of samples from the same manufacturer (manufacturer 1, 3, 4 and 5) appeared to be similar on dissolution behavior, indicating that the dissolution behavior of the majority of samples from different manufacturers was similar. The dissolution behavior of batch 1 sample was different from batch 2 and 3 samples in manufacturer 2, suggesting that the quality of different batches of samples in manufacturer 2 might be different. The fitting results of dissolution data of index components in samples from different manufacturers were consistent, and the Weibull model was the best. Conclusion:Index components in fifteen batches of samples from 5 manufacturers are continuously dissolved within 24 h, indicating that the samples have the characteristics of slow dissolution. The dissolution curves of samples from the same manufacturer are similar to each other, indicating that the quality of different batches of products from most manufacturers is stable. The dissolution behavior of benzoylmesaconine, benzoylaconine and benzoylhypaconine in samples form different manufacturers has some differences, which may be caused by the source of medicinal materials and preparation technology parameters.